BISTRO: BioImpedance To Maintain Renal Output Trial
Explore this Section
BISTRO: BioImpedance Spectroscopy To maintain Renal Output Trial
Welcome to the BISTRO trial!
Due to COVID-19 (Coronavirus), as of Monday 23rd March 2020, recruitment of patients to all of our active research studies has ceased. This is to allow our clinical colleagues to focus their care where it is most needed. Keele Clinical Trials Unit will be operating remotely. We are currently reviewing the trials we have open and are in contact with sponsors. The safety of our patients is always our priority. We apologise for any inconvenience caused during this challenging time. You can continue to contact us using individual staff email addresses or by using your usual study contact email address, to contact study teams. Should you have any other queries or questions please use the general Keele CTU enquiry email - firstname.lastname@example.org
The BISTRO trial is a NIHR HTA funded pragmatic, multicentre randomised controlled trial (RCT) designed to test whether taking regular measurements with a bioimpedance device, which gives information about body composition, improves outcomes for people who have newly started haemodialysis treatment for kidney failure.
The BISTRO trial is based in the UK and has opened for recruitment on 6th April 2017.
We launched the BISTRO trial sites in several waves, starting in the first quarter of 2017. Currently 34 UK sites are participating.
This website will be the central communication hub for all aspects of the trial. Feel free to browse the site and register your interest in participating if you haven’t done so already.
We will continue to add more information as the study progresses. Please contact us if you have any queries.
NEXT BISTRO OPEN SURGERY CALLS:
None planned at present
The BISTRO trial team
Last updated – 2019-12-17